Visirna Announces Dosing of the First Subjects in China Phase I Study of VSA003

SHANGHAI, CHINA – July 7ᵗʰ, Visirna today announced that it has dosed the first subjects in a China Phase I clinical study of VSA003, an RNAi-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3) being developed for the potential treatment of dyslipidemia and metabolic diseases. Professor Rui Chen, M.D., Principal Investigator at Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (PUMCH), said: "We've been paying close attention to innovative therapies in the cardiovascular and metabolic fields, especially the small nucleic acid drugs in China. I am pleased to learn that Visirna is advancing clinical development of VSA003 in China with its strategic partner - Arrowhead Pharmaceuticals. As the principal investigator of the first China clinical trial of VSA003, I am looking forward to the progress of the study and bringing better treatment option for patients with dyslipidemia in China." "Thanks to the volunteers and investigators, Visirna has successfully initiated a Phase I clinical trial and dosed the first subjects of VSA003 in China. As one of the core pipelines of Visirna, VSA003's global studies demonstrated promising safety profile and treatment potential to address significant unmet medical needs in cardiovascular and metabolic disease areas. We will continue to work closely with VSA003's investigators to advance its clinical development and look forward to providing Chinese patients with better treatment options." Dr. Xiaoming Zou, CEO of Visirna, said. Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases.

The release as fetched from its publisher. visirna.com ↗